|Articles|April 1, 2004

Coping with pelvic inflammatory disease in the adolescent

Specialists in adolescent medicine show you how to evaluate your sexually active female patients for PID and manage this common complication of sexually transmitted disease.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe

Related Content

Preventing constipation, dehydration, and snack chaos during summer travel

ByColleen Sloan, PA-C, RDN

July 8th 2026

SL1009 resubmitted to FDA for pyruvate dehydrogenase complex deficiency

ByMorgan Ebert, Executive Editor

July 8th 2026

FDA expands wilate approval to routine prophylaxis for all types of von Willebrand disease

ByMorgan Ebert, Executive Editor

July 8th 2026

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

ByBenjamin P. Saylor

July 8th 2026

FAQ: Which children with early puberty actually need testing and treatment?

ByContemporary Pediatrics Staff

July 7th 2026

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Coping with pelvic inflammatory disease in the adolescent

Related Content

Preventing constipation, dehydration, and snack chaos during summer travel

SL1009 resubmitted to FDA for pyruvate dehydrogenase complex deficiency

FDA expands wilate approval to routine prophylaxis for all types of von Willebrand disease

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

FAQ: Which children with early puberty actually need testing and treatment?

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

FAQ: Which children with early puberty actually need testing and treatment?

Researchers identify hypermobility-linked autonomic subtype of eosinophilic esophagitis in children

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

FDA clears IND for investigational SUMF1 gene therapy in multiple sulfatase deficiency

FDA expands wilate approval to routine prophylaxis for all types of von Willebrand disease